These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10870602)

  • 1. 48-week data released for combination treatment with efavirenz.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438-40. PubMed ID: 10870602
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-ranging studies.
    Manion D
    Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 4. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term success in routine clinical practice. Effectiveness trial passed].
    MMW Fortschr Med; 2000; 142(3 Suppl):30-1. PubMed ID: 10893961
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress in HIV therapy. Effective and simple therapy with efavirenz].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():36-7. PubMed ID: 11373774
    [No Abstract]   [Full Text] [Related]  

  • 7. Paediatric treatment issues.
    Walters S
    Int J Clin Pract Suppl; 1999 Jun; 103():26-9. PubMed ID: 10622040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz shows promising results.
    AIDS Patient Care STDS; 1998 Jan; 12(1):64-5. PubMed ID: 11361892
    [No Abstract]   [Full Text] [Related]  

  • 9. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustiva added to three-drug combination.
    AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily drug for persons with HIV.
    Am Fam Physician; 1998 Dec; 58(9):2174-5. PubMed ID: 9861886
    [No Abstract]   [Full Text] [Related]  

  • 12. [ACTG-study 5095: superiority of efavirenz containing drug scheme].
    Dtsch Med Wochenschr; 2003 May; 128(19):1076. PubMed ID: 12774799
    [No Abstract]   [Full Text] [Related]  

  • 13. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with efavirenz in end-stage renal disease.
    Das S; Ghanem M; Huengsberg M
    Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
    [No Abstract]   [Full Text] [Related]  

  • 15. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G; Khoo S; Jack C; Lalloo U
    J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I want a new drug. An overview of three new anti-HIV drugs.
    Simmons P
    Res Initiat Treat Action; 1998 Jun; 4(3):9-11. PubMed ID: 11365539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily dosing and the treatment of HIV disease.
    Laurence J
    AIDS Read; 2006 Sep; 16(9):444-5. PubMed ID: 17024761
    [No Abstract]   [Full Text] [Related]  

  • 20. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
    Maggiolo F; Migliorino M; Maserati R; Pan A; Rizzi M; Provettoni G; Rizzi L; Suter F;
    Antivir Ther; 2001 Dec; 6(4):249-53. PubMed ID: 11878406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.